Thoratec share price went up yesterday and closed at US$ 26.12 http://www.marketwatch.com/investing/stock/THOR?siteid=mktw
Thoratec filed a PMA with the FDA in April 09 for the approval of the DT indication for their device Heartmate II, with a Supplemental PMA expected end June 09 (about now) to capture two-year follow-up clinical data for all 200 trial participants. The device received the FDA approval for the BTT indication in April 08.
Heartware US closed at US$ 26.68 http://www.marketwatch.com/investing/stock/htwr
Yes, there is money to be made in LVADs... if companies are managed properly, that is.
VCR Price at posting:
8.3¢ Sentiment: None Disclosure: Not Held